David M Schuster

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8654322/publications.pdf

Version: 2024-02-01

155	5,360	81839	95218
papers	citations	39 h-index	68 g-index

160	160	160	5286
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 540-557.	3.3	348
2	Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1385-1392.	0.4	242
3	Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. Journal of Nuclear Medicine, 2007, 48, 56-63.	2.8	207
4	Hyperspectral imaging and quantitative analysis for prostate cancer detection. Journal of Biomedical Optics, 2012, 17, 0760051.	1.4	199
5	Anti-3-[¹⁸ F]FACBC Positron Emission Tomography-Computerized Tomography and ¹¹¹ In-Capromab Pendetide Single Photon Emission Computerized Tomography-Computerized Tomography for Recurrent Prostate Carcinoma: Results of a Prospective Clinical Trial. Journal of Urology, 2014, 191, 1446-1453.	0.2	165
6	Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54 Biochemically Recurrent Prostate Cancer. Journal of Urology, 2017, 197, 676-683.	0.2	165
7	Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹Inâ€“Capromab Pendetide SPECT/CT. Radiology, 2011, 259, 852-861.	3.6	153
8	Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapyâ€“treated macaques. Nature Methods, 2015, 12, 427-432.	9.0	153
9	Anti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid: Physiologic Uptake Patterns, Incidental Findings, and Variants That May Simulate Disease. Journal of Nuclear Medicine, 2014, 55, 1986-1992.	2.8	138
10	Recurrent prostate cancer detection with anti-3-[18F]FACBC PET/CT: comparison with CT. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1773-1783.	3.3	138
11	F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer. Head and Neck, 2005, 27, 494-502.	0.9	121
12	The Impact of Positron Emission Tomography with ¹⁸ F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. Journal of Urology, 2019, 201, 322-331.	0.2	113
13	Transport mechanisms of trans-1-amino-3-fluoro[1-14C]cyclobutanecarboxylic acid in prostate cancer cells. Nuclear Medicine and Biology, 2012, 39, 109-119.	0.3	111
14	18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet, The, 2021, 397, 1895-1904.	6.3	107
15	MRâ€based attenuation correction for hybrid PETâ€MR brain imaging systems using deformable image registration. Medical Physics, 2010, 37, 2101-2109.	1.6	101
16	Update on ¹⁸F-Fluciclovine PET for Prostate Cancer Imaging. Journal of Nuclear Medicine, 2018, 59, 733-739.	2.8	101
17	Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. Annals of Surgical Oncology, 2015, 22, 2295-2301.	0.7	93
18	Differences in Neural Activation for Object-Directed Grasping in Chimpanzees and Humans. Journal of Neuroscience, 2013, 33, 14117-14134.	1.7	88

#	Article	IF	Citations
19	Biodistribution and Radiation Dosimetry of the Synthetic Nonmetabolized Amino Acid Analogue Anti-18F-FACBC in Humans. Journal of Nuclear Medicine, 2007, 48, 1017-1020.	2.8	86
20	Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents. Medicinal Research Reviews, 2012, 32, 868-905.	5.0	83
21	Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer. Clinical Nuclear Medicine, 2017, 42, e22-e28.	0.7	77
22	Radionuclide imaging for hyperparathyroidism (HPT): Which is the best technetium-99m sestamibi modality?. Surgery, 2006, 140, 856-865.	1.0	73
23	Gastrointestinal Tract Malignancies and Positron Emission Tomography: An Overview. Seminars in Nuclear Medicine, 2006, 36, 169-181.	2.5	70
24	Differences in Transport Mechanisms of trans-1-Amino-3-[18F]Fluorocyclobutanecarboxylic Acid in Inflammation, Prostate Cancer, and Glioma Cells: Comparison with l-[Methyl-11C]Methionine and 2-Deoxy-2-[18F]Fluoro-d-Glucose. Molecular Imaging and Biology, 2014, 16, 322-329.	1.3	70
25	Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 85-96.	1.0	63
26	PET Tracers Beyond FDG in Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 507-521.	2.5	62
27	Initial Experience with the Radiotracer Anti-1-amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid (Anti-[18F]FACBC) with PET in Renal Carcinoma. Molecular Imaging and Biology, 2009, 11, 434-438.	1.3	55
28	Local Recurrence Patterns in Breast Cancer Patients Treated with Oncoplastic Reduction Mammaplasty and Radiotherapy. Annals of Surgical Oncology, 2014, 21, 93-99.	0.7	55
29	Anti-3-¹⁸F-FACBC (¹⁸F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study. Journal of Nuclear Medicine, 2016, 57, 1357-1363.	2.8	53
30	Prompt-gamma compensation in Rb-82 myocardial perfusion 3D PET/CT. Journal of Nuclear Cardiology, 2010, 17, 247-253.	1.4	51
31	Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2. Nuclear Medicine and Biology, 2013, 40, 670-675.	0.3	51
32	Comparative evaluation of transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid and l-[methyl-11C]methionine in human glioma cell lines. Brain Research, 2013, 1535, 24-37.	1.1	48
33	Gallium and other agents in diseases of the lung. Seminars in Nuclear Medicine, 2002, 32, 193-211.	2.5	46
34	[14C]Fluciclovine (alias anti-[14C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells. Nuclear Medicine and Biology, 2015, 42, 887-892.	0.3	46
35	Imaging of Prostate Cancer Using Fluciclovine. PET Clinics, 2017, 12, 145-157.	1.5	46
36	ACR Appropriateness Criteria Â® Prostate Cancerâ€"Pretreatment Detection, Surveillance, andÂStaging. Journal of the American College of Radiology, 2017, 14, S245-S257.	0.9	44

#	Article	IF	Citations
37	PET-CT vs contrast-enhanced CT: What is the role for each after chemoradiation for advanced oropharyngeal cancer?. Head and Neck, 2006, 28, 487-495.	0.9	42
38	[18F]Fluciclovine PET discrimination between high- and low-grade gliomas. EJNMMI Research, 2018, 8, 67.	1.1	42
39	A Simple Method for Estimating Dose Delivered to Hepatocellular Carcinoma after Yttrium-90 Glass-Based Radioembolization Therapy: Preliminary Results of a Proof of Concept Study. Journal of Vascular and Interventional Radiology, 2014, 25, 277-287.	0.2	40
40	[18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imagingâ€"version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 579-591.	3.3	39
41	Impact of ¹⁸F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial. Journal of Nuclear Medicine, 2017, 58, 412-418.	2.8	36
42	ACR Appropriateness Criteria Â® PretreatmentÂStaging of Muscle-Invasive BladderÂCancer. Journal of the American College of Radiology, 2018, 15, S150-S159.	0.9	36
43	Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs. Journal of Nuclear Medicine, 2016, 57, 61S-66S.	2.8	35
44	PET Molecular Imagingâ€"Directed Biopsy: A Review. American Journal of Roentgenology, 2017, 209, 255-269.	1.0	34
45	Accumulation of Trans-1-Amino-3-[18F]Fluorocyclobutanecarboxylic Acid in Prostate Cancer due to Androgen-Induced Expression of Amino Acid Transporters. Molecular Imaging and Biology, 2014, 16, 756-764.	1.3	33
46	Absent coronary artery calcium excludes inducible myocardial ischemia on computed tomography/positron emission tomography. International Journal of Cardiology, 2011, 147, 424-427.	0.8	32
47	Do 18F-FDG PET/CT Parameters in Oropharyngeal and Oral Cavity Squamous Cell Carcinomas Indicate HPV Status?. Clinical Nuclear Medicine, 2015, 40, e196-e200.	0.7	32
48	Prospective evaluation of fluciclovine (18 F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients. European Journal of Radiology, 2018, 102, 1-8.	1.2	32
49	90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival. Clinical Nuclear Medicine, 2016, 41, 21-27.	0.7	31
50	Imaging of Prostate Cancer Using Fluciclovine. Urologic Clinics of North America, 2018, 45, 489-502.	0.8	31
51	⁹⁰Y Radioembolization: Multimodality Imaging Pattern Approach with Angiographic Correlation for Optimized Target Therapy Delivery. Radiographics, 2015, 35, 1602-1618.	1.4	29
52	Quantitative Dosimetry for Yttrium-90 Radionuclide Therapy: Tumor Dose Predicts Fluorodeoxyglucose Positron Emission Tomography Response in Hepatic Metastatic Melanoma. Journal of Vascular and Interventional Radiology, 2014, 25, 288-295.	0.2	28
53	Automatic segmentation of the prostate on CT images using deep learning and multi-atlas fusion. Proceedings of SPIE, 2017, 10133, .	0.8	28
54	Bayesian penalised likelihood reconstruction (Q.Clear) of ¹⁸F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation. British Journal of Radiology, 2018, 91, 20170727.	1.0	28

#	Article	IF	Citations
55	Pilot Study of the Utility of the Synthetic PET Amino-Acid Radiotracer Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid for the Noninvasive Imaging of Pulmonary Lesions. Molecular Imaging and Biology, 2013, 15, 633-643.	1.3	26
56	Automatic 3D segmentation of ultrasound images using atlas registration and statistical texture prior. , 2011, 7964, .		25
57	Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2016, 96, 206-213.	0.4	25
58	Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer. American Journal of Roentgenology, 2019, 213, 851-858.	1.0	24
59	The Use of the Diagnostic Radionuclide Ascites Scan to Facilitate Treatment Decisions for Hepatic Hydrothorax. Clinical Nuclear Medicine, 1998, 23, 16-18.	0.7	24
60	Involving Users in the Implementation of an Imaging Order Entry System. Journal of the American Medical Informatics Association: JAMIA, 2003, 10, 315-321.	2.2	22
61	The malady of incomplete, inadequate, and inaccurate radiology requisition histories: a computerized treatment.. American Journal of Roentgenology, 1996, 167, 855-859.	1.0	20
62	Breast Angiosarcoma. Clinical Nuclear Medicine, 2009, 34, 443-445.	0.7	20
63	Prognostic Value of 18F-Fluorodeoxyglucose Positron Emission Tomographyâ€“Computed Tomography in Predicting Survival in Patients with Unresectable Metastatic Melanoma to the Liver Undergoing Yttrium-90 Radioembolization. Journal of Vascular and Interventional Radiology, 2012, 23, 943-948.	0.2	20
64	ACR Appropriateness Criteria Â® Post-treatmentÂFollow-up Prostate Cancer. Journal of the American College of Radiology, 2018, 15, S132-S149.	0.9	20
65	Comparison of Tc-99m MAA Planar Versus SPECT/CT Imaging for Lung Shunt Fraction Evaluation Prior to Y-90 Radioembolization: Are We Overestimating Lung Shunt Fraction?. CardioVascular and Interventional Radiology, 2021, 44, 254-260.	0.9	20
66	A molecular image-directed, 3D ultrasound-guided biopsy system for the prostate. Proceedings of SPIE, 2012, 2012, .	0.8	19
67	PET Tracer ¹⁸F-Fluciclovine Can Detect Histologically Proven Bone Metastatic Lesions: A Preclinical Study in Rat Osteolytic and Osteoblastic Bone Metastasis Models. Theranostics, 2017, 7, 2048-2064.	4.6	18
68	Amino Acid Metabolism as a Target for Breast Cancer Imaging. PET Clinics, 2018, 13, 437-444.	1.5	18
69	18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?. European Journal of Radiology, 2015, 84, 1171-1176.	1.2	17
70	A semiautomatic segmentation method for prostate in <scp>CT</scp> images using local texture classification and statistical shape modeling. Medical Physics, 2018, 45, 2527-2541.	1.6	17
71	Sarcoid-Like Reaction in the Spleen Following Chemotherapy for Non-Hodgkinâ€™s Lymphoma. Clinical Nuclear Medicine, 2007, 32, 569-571.	0.7	16
72	Is There a Role for PET/CT Parameters to Characterize Benign, Malignant, and Metastatic Parotid Tumors?. American Journal of Roentgenology, 2016, 207, 635-640.	1.0	16

#	Article	IF	Citations
73	90 Y radioembolization dosimetry using a simple semi-quantitative method in intrahepatic cholangiocarcinoma: Glass versus resin microspheres. Nuclear Medicine and Biology, 2018, 59, 22-28.	0.3	16
74	Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know. Seminars in Interventional Radiology, 2020, 37, 543-554.	0.3	16
75	Esophageal Scarring Causing False-Positive Uptake on I-131 Whole-Body Imaging. Clinical Nuclear Medicine, 1998, 23, 334.	0.7	16
76	[¹⁸ F]Fluciclovine Positron Emission Tomography/Computerized Tomography for Preoperative Staging in Patients with Intermediate to High Risk Primary Prostate Cancer. Journal of Urology, 2020, 204, 734-740.	0.2	16
77	Case Study of Anti-1-Amino-3-F-18 Fluorocyclobutane-1-Carboxylic Acid (Anti-[F-18] FACBC) to Guide Prostate Cancer Radiotherapy Target Design. Clinical Nuclear Medicine, 2009, 34, 279-284.	0.7	15
78	Pilot Evaluation of Anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in Recurrent Prostate Carcinoma. Molecular Imaging and Biology, 2011, 13, 1272-1277.	1.3	15
79	A combined learning algorithm for prostate segmentation on 3D <scp>CT</scp> images. Medical Physics, 2017, 44, 5768-5781.	1.6	15
80	Incidence of Radioembolization-Induced Liver Disease and Liver Toxicity Following Repeat 90Y-Radioembolization. Clinical Nuclear Medicine, 2020, 45, 100-104.	0.7	15
81	CT with Histopathologic Correlation of FDG Uptake in a Patient with Pulmonary Granuloma and Pleural Plaque Caused by Remote Talc Pleurodesis. American Journal of Roentgenology, 2004, 182, 92-94.	1.0	14
82	Xanthogranulomatous Pyelonephritis Characterized on PET/CT. Clinical Nuclear Medicine, 2005, 30, 728-729.	0.7	14
83	Role of novel imaging in the management of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 611-618.	0.8	14
84	18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review. Prostate Cancer and Prostatic Diseases, 2021, 24, 997-1006.	2.0	14
85	Tumor-to-Normal Ratio Relationship between Planning Technetium-99 Macroaggregated Albumin and Posttherapy Yttrium-90 Bremsstrahlung SPECT/CT. Journal of Vascular and Interventional Radiology, 2021, 32, 752-760.	0.2	14
86	[18F]-Fluciclovine PET discrimination of recurrent intracranial metastatic disease from radiation necrosis. EJNMMI Research, 2020, 10, 148.	1.1	14
87	¹⁸F-Fluciclovine Parameters on Targeted Prostate Biopsy Associated with True Positivity in Recurrent Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1531-1536.	2.8	13
88	Role of ¹⁸F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Management of Oligometastatic Prostate Cancer: AJR Expert Panel Narrative Review. American Journal of Roentgenology, 2021, 216, 851-859.	1.0	13
89	Molecular imaging and fusion targeted biopsy of the prostate. Clinical and Translational Imaging, 2017, 5, 29-43.	1.1	12
90	Fasting Enhances the Contrast of Bone Metastatic Lesions in 18F-Fluciclovine-PET: Preclinical Study Using a Rat Model of Mixed Osteolytic/Osteoblastic Bone Metastases. International Journal of Molecular Sciences, 2017, 18, 934.	1.8	12

#	Article	IF	Citations
91	Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on ¹⁸F-Fluciclovine PET/CT Guidance. Journal of Nuclear Medicine, 2021, 62, 1089-1096.	2.8	12
92	Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer. Journal of Urology, 2019, 202, 413-421.	0.2	12
93	PET-directed, 3D Ultrasound-guided prostate biopsy. Diagnostic Imaging Europe, 2013, 29, 12-15.	0.0	12
94	Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMAÂand Beyond. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 366-382.	1.8	12
95	Magnetic resonance cholangiography. Abdominal Imaging, 1995, 20, 353-356.	2.0	11
96	Unusual Presentations of Metastatic Prostate Carcinoma as Detected by anti-3 F-18 FACBC PET/CT. Clinical Nuclear Medicine, 2011, 36, 800-802.	0.7	11
97	Molecular imaging in breast cancer. Radiologic Clinics of North America, 2004, 42, 885-908.	0.9	10
98	Reproducibility and Reliability of Anti-3-[18F]FACBC Uptake Measurements in Background Structures and Malignant Lesions on Follow-Up PET-CT in Prostate Carcinoma: an Exploratory Analysis. Molecular Imaging and Biology, 2015, 17, 277-283.	1.3	10
99	Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization. CardioVascular and Interventional Radiology, 2021, 44, 1194-1203.	0.9	10
100	Role of Resin Microsphere Y90 Dosimetry in Predicting Objective Tumor Response, Survival and Treatment Related Toxicity in Surgically Unresectable Colorectal Liver Metastasis: A Retrospective Single Institution Study. Cancers, 2021, 13, 4908.	1.7	10
101	PET Imaging for Prostate Cancer. Radiologic Clinics of North America, 2021, 59, 801-811.	0.9	10
102	A PET/CT Directed, 3D Ultrasound-Guided Biopsy System for Prostate Cancer. Lecture Notes in Computer Science, 2011, 6363, 100-108.	1.0	10
103	Investigation of Emissionâ€“Transmission Misalignment Artifacts on Rubidium-82 Cardiac PET with Adenosine Pharmacologic Stress. Molecular Imaging and Biology, 2008, 10, 201-208.	1.3	9
104	Radiation Field Design and Patterns of Locoregional Recurrence Following Definitive Radiotherapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 309-314.	0.4	9
105	18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. Practical Radiation Oncology, 2020, 10, 354-362.	1.1	9
106	Yttrium-90 dosimetry and implications on tumour response and survival after radioembolisation of chemo-refractory hepatic metastases from breast cancer. Nuclear Medicine Communications, 2021, 42, 402-409.	0.5	9
107	Combining population and patient-specific characteristics for prostate segmentation on 3D CT images. , 2016, 9784, .		8
108	Radionuclide Therapies in Molecular Imaging and Precision Medicine. PET Clinics, 2017, 12, 93-103.	1.5	8

#	Article	IF	Citations
109	ACR Appropriateness CriteriaÂ® Recurrent Lower Urinary Tract Infections in Females. Journal of the American College of Radiology, 2020, 17, S487-S496.	0.9	8
110	A Rare Presentation of Myocardial Plasmacytoma Assessed by FDG PET/CT. Clinical Nuclear Medicine, 2014, 39, 643-645.	0.7	7
111	Improved Tumor Response in Patients on Metformin Undergoing Yttrium-90 Radioembolization Segmentectomy for Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2021, 44, 1937-1944.	0.9	7
112	Same day yttrium-90 radioembolization with single photon emission computed tomography/computed tomography: An opportunity to improve care during the COVID-19 pandemic and beyond. World Journal of Gastrointestinal Oncology, 2021, 13, 440-452.	0.8	6
113	Deep learning-based three-dimensional segmentation of the prostate on computed tomography images. Journal of Medical Imaging, 2019, 6, 1.	0.8	6
114	A semiautomatic algorithm for three-dimensional segmentation of the prostate on CT images using shape and local texture characteristics. , 2018, 10576, .		6
115	Jejunal Diverticular Hemorrhage Localized by Red Blood Cell Scintigraphy. Clinical Nuclear Medicine, 2001, 26, 936-937.	0.7	5
116	Central Line Injection Artifact Simulating Paratracheal Adenopathy on FDG PET Imaging. Clinical Nuclear Medicine, 2004, 29, 735-737.	0.7	5
117	Posterior bladder layering of excreted 18F-FDG on PET/CT. Nuclear Medicine Communications, 2010, 31, 859-863.	0.5	5
118	Molecular imaging of advanced prostate cancer. Current Problems in Cancer, 2015, 39, 29-32.	1.0	5
119	The Nuclear Medicine Therapy Care Coordination Service. Academic Radiology, 2015, 22, 771-778.	1.3	5
120	ACR Appropriateness CriteriaÂ® Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia. Journal of the American College of Radiology, 2019, 16, S378-S383.	0.9	5
121	Accuracy evaluation of a 3D ultrasound-guided biopsy system. Proceedings of SPIE, 2013, 8671, .	0.8	4
122	Is there a role for PET/CT parameters to differentiate thyroid cartilage invasion from penetration?. European Journal of Radiology, 2016, 85, 319-323.	1.2	4
123	The Integrative Hospital Explored via Acupuncture. Journal of Alternative and Complementary Medicine, 1996, 2, 503-514.	2.1	3
124	111In OctreoScan SPECT-MRI Fusion for the Detection of a Pancreatic Insulinoma. Clinical Nuclear Medicine, 2012, 37, e53-e56.	0.7	3
125	Current Clinical Practice Patterns of Self-Identified Nuclear Medicine Specialists. American Journal of Roentgenology, 2018, 211, 978-985.	1.0	3
126	Characterizing and Mitigating Bladder Radioactivity on ¹⁸F-Fluciclovine PET/CT. Journal of Nuclear Medicine Technology, 2020, 48, 24-29.	0.4	3

#	Article	IF	Citations
127	Determination of tumour dose response threshold and implication on survival in patients with HCC treated with Y90 radiation segmentectomy. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 892-898.	0.5	3
128	ACR Appropriateness CriteriaÂ® Staging and Surveillance of Testicular Cancer: 2021 Update. Journal of the American College of Radiology, 2022, 19, S194-S207.	0.9	3
129	Choroidal Melanoma With Hematogenous Spread to the Liver: F-18 FDG PET/CT Findings. Clinical Nuclear Medicine, 2006, 31, 347-348.	0.7	2
130	Biodistribution and human dosimetry of enantiomer-1 of the synthetic leucine analog anti-1-amino-2-fluorocyclopentyl-1-carboxylic acid. Nuclear Medicine and Biology, 2011, 38, 1035-1041.	0.3	2
131	Imaging quality of F-18-FDG PET/CT in the inpatient versus outpatient setting. Annals of Nuclear Medicine, 2013, 27, 508-514.	1.2	2
132	Focal Hepatic Hot Spot From Superior Vena Cava Occlusion Visualized on Ventilation/Perfusion Scintigraphy With Contrast-Enhanced CT Correlate. Clinical Nuclear Medicine, 2016, 41, 401-402.	0.7	2
133	A semiautomatic approach for prostate segmentation in MR images using local texture classification and statistical shape modeling. , 2019, 10951, .		2
134	Prostate Cancer Liver Metastases Presenting as Relatively Photopenic Lesions on 18F-Fluciclovine PET/CT. Clinical Nuclear Medicine, 2021, 46, e240-e241.	0.7	2
135	Clinical utility of F-Fluciclovine PET/CT in recurrent prostate cancer with very low (â‰¤0.3 ng/mL) prostate-specific antigen levels. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 406-414.	1.0	2
136	Randomized Trial of Conventional Versus Conventional Plus Fluciclovine (18F) Positron Emission Tomography/Computed Tomographyâ€“Guided Postprostatectomy Radiation Therapy for Prostate Cancer: Volumetric and Patient-Reported Analyses of Toxic Effects. International Journal of Radiation Oncology Biology Physics, 2022, 113, 1003-1014.	0.4	2
137	Volumetric analysis of the PET-CT defined target in intensity modulated radiotherapy for head and neck cancer. International Journal of Radiation Oncology Biology Physics, 2004, 60, S492-S492.	0.4	1
138	Four-dimensional (4D) Motion Detection to Correct Respiratory Effects in Treatment Response Assessment Using Molecular Imaging Biomarkers. TCRT Express, 2013, 13, 571-82.	1.5	1
139	Random walk based segmentation for the prostate on 3D transrectal ultrasound images. Proceedings of SPIE, 2016, 9786, .	0.8	1
140	Re: â€œCost-Savings Analysis of Renal Scintigraphy, Stratified byÂRenal Function Thresholds: Mercaptoacetyltriglycine Versus Diethylene Triamine Penta-Acetic Acidâ€• Journal of the American College of Radiology, 2017, 14, 146.	0.9	1
141	Multisite experience of fluciclovine (18F) PET/CT imaging in biochemically recurrent prostate cancer: Impact of clinical factors and intersite variation.. Journal of Clinical Oncology, 2017, 35, 163-163.	0.8	1
142	Malignant Supraclavicular Lymph Node Visualization During Tc-99m HDP Bone Imaging. Clinical Nuclear Medicine, 2000, 25, 376-377.	0.7	1
143	Incidental Detection of Lung Adenocarcinoma Presenting as an Anterior Mediastinal Mass on 18F-Fluciclovine PET/CT in a Patient With Primary Prostate Cancer. Clinical Nuclear Medicine, 2020, 45, e525-e527.	0.7	1
144	Exploratory study of F-fluciclovine pet/ct for response assessment to docetaxel in patients with metastatic castration-resistant prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 218-229.	1.0	1

#	Article	IF	Citations
145	Deep-learning-based extraprostatic nodal lesion segmentation on 18F-fluciclovine PET. , 2022, , .		1
146	One Possible Future. Journal of Alternative and Complementary Medicine, 1998, 4, 255-256.	2.1	0
147	Metastatic Breast Lesion to the Falx Detected with PET-CT. Nuclear Medicine and Molecular Imaging, 2012, 46, 147-149.	0.6	0
148	Heme products post-radiofrequency ablation obscure tumor recurrence on MR but not on PET-CT. Nuclear Medicine and Molecular Imaging, 2012, 46, 152-154.	0.6	0
149	SU-FF-J-122: Deformable Image Registration Using FDG-PET/MRI for Metastatic Breast Cancer Detection. Medical Physics, 2007, 34, 2396-2396.	1.6	0
150	PERCIST criteria to predict survival at 3 months following intra-arterial resin-based yttrium-90 (Y-90) radioembolization therapy of unresectable intrahepatic cholangiocarcinoma refractory to standard chemotherapy: A proof of concept study.. Journal of Clinical Oncology, 2013, 31, e15141-e15141.	0.8	0
151	Artifactual Perfusion Defect from a Hypertrophic First Costosternal Articulation. Clinical Nuclear Medicine, 1997, 22, 642.	0.7	0
152	Radiologic Assessment of Esophageal Cancer. , 2015, , 105-121.		0
153	Radiologic Assessment of Esophageal Cancer. , 2020, , 139-157.		0
154	Ring Sclerosis in Prostate Cancer. Clinical Nuclear Medicine, 2021, 46, e286-e289.	0.7	0
155	82Rubidium chloride PET discrimination of recurrent intracranial malignancy from radiation necrosis. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, , .	0.4	0